← All trials
NCT05766683
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2023
- Primary completion
- Jun 20, 2023
- Completion date
- Dec 31, 2023
- First posted
- Mar 13, 2023
- Last posted
- Sep 29, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Henry Ford Health SystemLead sponsor
- Henry Ford Health SystemReponsible party - principal investigator
- Henry Ford Health SystemSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.